Skip to content
    Real-World Studies

    Regimen-Specific Toxicity Profiles of Immune Checkpoint Inhibitors in Lung Cancer

    Jiang et alJournal of Thoracic Disease

    A pharmacovigilance disproportionality analysis evaluating 34,223 adverse event reports from the FDA Adverse Event Reporting System (FAERS) database characterized real-world toxicity profiles of immune checkpoint inhibitor (ICI) monotherapy and combination regimens in lung cancer. Across the evaluated agents (pembrolizumab, atezolizumab, nivolumab, and their combinations), distinct organ-specific toxicity patterns were observed: PD-1 and PD-L1 inhibitors primarily presented with endocrine and respiratory adverse events, whereas ipilimumab was associated with dermatologic and hepatobiliary effects.
    Cardiovascular toxicities emerged across all checkpoint inhibitor regimens. Stress cardiomyopathy was reported with all agents, with pembrolizumab demonstrating the highest disproportionality signal. In stratified demographic analysis, male sex was associated with a statistically significant 73% reduction in the odds of reported atezolizumab-associated stress cardiomyopathy (OR = 0.27, P < 0.01).
    Analyses of combination regimens revealed substantial heterogeneity and accelerated toxicity onset. Compared with monotherapies, combination therapies were associated with an increased odds of reporting cardiac and gastrointestinal adverse events, alongside a shorter reported time-to-onset. Specific combination signals included earlier-onset duodenitis with pembrolizumab plus chemotherapy, duodenal ulcer hemorrhage uniquely associated with atezolizumab plus bevacizumab and platinum-based chemotherapy, and ventricular fibrillation identified with the nivolumab-ipilimumab dual-immunotherapy combination. These findings indicate that real-world ICI toxicity is regimen-specific and support differentiated clinical surveillance strategies based on the exact combination administered.

    Key Takeaways

    • Male patients receiving atezolizumab exhibited 73% lower odds of reported stress cardiomyopathy compared with female patients (OR = 0.27, P < 0.01), while stress cardiomyopathy occurred across all evaluated agents and demonstrated the highest disproportionality signal with pembrolizumab.
    • Regimen-specific safety signals demonstrated earlier onset of duodenitis with pembrolizumab plus chemotherapy, a unique association of duodenal ulcer hemorrhage with atezolizumab-bevacizumab-platinum, and reporting of ventricular fibrillation with nivolumab plus ipilimumab.
    • Combination checkpoint inhibitor regimens demonstrated a shorter reported time-to-onset and increased odds of reporting cardiac and gastrointestinal toxicities compared to monotherapy.
    Read the original sourceJournal of Thoracic Disease